Penumbra, Inc. (NYSE:PEN) Director Thomas Wilder Sells 372 Shares

Penumbra, Inc. (NYSE:PEN) Director Thomas Wilder sold 372 shares of the stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $240.16, for a total transaction of $89,339.52. Following the completion of the transaction, the director directly owned 372 shares of the company’s stock, valued at approximately $89,339.52. The trade was a 50.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Penumbra Stock Performance

Shares of NYSE:PEN opened at $252.99 on Friday. The firm has a market cap of $9.87 billion, a PE ratio of 67.28, a price-to-earnings-growth ratio of 2.28 and a beta of 0.40. The firm’s 50 day simple moving average is $246.04 and its 200-day simple moving average is $265.62. Penumbra, Inc. has a one year low of $184.80 and a one year high of $310.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.04 and a current ratio of 6.75.

Penumbra (NYSE:PEN) last issued its earnings results on Tuesday, July 29th. The company reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.81 by $0.05. The business had revenue of $339.46 million for the quarter, compared to analyst estimates of $327.37 million. Penumbra had a net margin of 11.54% and a return on equity of 11.55%. The company’s quarterly revenue was up 13.4% compared to the same quarter last year. During the same period last year, the company posted $0.64 earnings per share. As a group, equities analysts predict that Penumbra, Inc. will post 3.67 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. William Blair raised shares of Penumbra to a “strong-buy” rating in a report on Friday, July 18th. Citigroup decreased their price objective on shares of Penumbra from $320.00 to $285.00 and set a “neutral” rating for the company in a research note on Wednesday, July 9th. Robert W. Baird raised their price objective on shares of Penumbra from $283.00 to $285.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 30th. Royal Bank Of Canada decreased their price objective on shares of Penumbra from $330.00 to $325.00 and set an “outperform” rating for the company in a research note on Wednesday, July 30th. Finally, Truist Financial set a $310.00 price objective on shares of Penumbra and gave the stock a “buy” rating in a research note on Wednesday, July 30th. Four equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Penumbra presently has a consensus rating of “Moderate Buy” and an average target price of $300.47.

Hedge Funds Weigh In On Penumbra

Institutional investors have recently bought and sold shares of the business. Synergy Investment Management LLC purchased a new position in Penumbra during the first quarter valued at approximately $27,000. First Horizon Advisors Inc. increased its holdings in Penumbra by 404.8% during the first quarter. First Horizon Advisors Inc. now owns 106 shares of the company’s stock valued at $28,000 after buying an additional 85 shares during the period. Parkside Financial Bank & Trust increased its holdings in Penumbra by 70.2% during the second quarter. Parkside Financial Bank & Trust now owns 160 shares of the company’s stock valued at $41,000 after buying an additional 66 shares during the period. AlphaQuest LLC purchased a new position in Penumbra during the first quarter valued at approximately $66,000. Finally, EverSource Wealth Advisors LLC increased its holdings in Penumbra by 209.1% during the second quarter. EverSource Wealth Advisors LLC now owns 272 shares of the company’s stock valued at $70,000 after buying an additional 184 shares during the period. 88.88% of the stock is owned by hedge funds and other institutional investors.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.